Cyclacel Pharmaceuticals, Inc. (CYCC)

Market Cap	52.54M
Revenue (ttm)	43,000
Net Income (ttm)	-11.21M
Shares Out	207.34M
EPS (ttm)	-2.09
PE Ratio	n/a
Forward PE	n/a
Dividend	$0.15 (59.20%)
Ex-Dividend Date	Apr 29, 2025

Volume	1,261,076
Open	0.3000
Previous Close	0.3000
Day's Range	0.2500 - 0.3256
52-Week Range	0.1700 - 3.0800
Beta	0.53
Analysts	Strong Buy
Price Target	11.00 (+4,240.96%)
Earnings Date	May 20, 2025

About CYCC

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, epigenetics, and mitosis biology in the United States and the United Kingdom. Its lead product, Plogosertib or plogo, is a PLK1 inhibitor, in solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: CYCC
• Website: https://www.cyclacel.com

Financial Performance

In 2024, Cyclacel Pharmaceuticals's revenue was $43,000, a decrease of -89.76% compared to the previous year's $420,000. Losses were -$11.21 million, -50.73% less than in 2023.

Analyst Forecast

According to one analyst, the rating for CYCC stock is "Strong Buy" and the 12-month stock price forecast is $11.0.

Price Target

$11.0

(4,240.96% upside)

Analyst Consensus: Strong Buy